Clinical trials
Chronic Liver Disease and Cirrhosis clinical trials
Below are recruiting chronic liver disease and cirrhosis clinical trials, each written for real people, not researchers. We’re tracking 200 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05623150Recruiting
Biopsy-based study for alcohol and metabolic liver disease
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
NiceAges 18 years+ - NCT05727722RecruitingPhase 1
Micro-packaged liver cell transplant for adult liver failure
This Phase 1 study tests a new way to place liver cells (in small protective “micro-packages”) inside the belly to treat liver failure. It aims to see whether the treatment is safe and potentially helps liver function in adults with worsening chronic or acute-on-chronic liver failure.
ShanghaiAges 18–65 - NCT05733832Recruiting
Transitional care after hospital discharge for serious liver disease
This trial tests an extra support program after you leave the hospital to help people with advanced liver disease avoid complications and stay on track. It may help by providing structured follow-up soon after discharge.
Chicago, IllinoisAges 18 years+ - NCT05832229RecruitingPhase 2
Studying rosuvastatin to slow liver scarring in cirrhosis
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
La Jolla, CaliforniaAges 18–75 - NCT05865691Recruiting
Study blood and organ changes in chronic liver disease
This study looks at how blood clotting, inflammation, and blood vessels change in people with chronic liver disease or cirrhosis. Your blood tests may help researchers understand what drives the disease and could guide future care.
ClichyAges 18 years+ - NCT05870969Recruiting
Digital monitoring to catch liver cancer risk early
This study tests a digital (computer/phone-based) system to help track people with higher risk of liver cancer so cancers can be found earlier. It may help by guiding regular check-ins and making early diagnosis more efficient.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05895136RecruitingPhase 2
Albumin plus blood thinner for severe cirrhosis after hospital recovery
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
ClichyAges 18–80 - NCT05998330Recruiting
Palliative care support for advanced liver disease patients
This study tests whether adding palliative care (extra support for symptoms and planning) during a hospital stay helps people with advanced liver disease and their caregivers feel better and plan ahead.
Boston, MassachusettsAges 18 years+ - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT05181826Recruiting
Blood collection study for cancer and benign diseases
This study collects blood samples from people with different health conditions (cancer, diabetes, liver disease, etc.) and from healthy volunteers. The goal is to find markers in the blood that could help detect or monitor diseases.
Redondo Beach, CaliforniaAges 18 years+ - NCT06368882RecruitingPhase 4
Peg-interferon for hepatitis B with fatty liver
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
NingboAges 18–60 - NCT06432582Recruiting
Liver disease blood marker study for people with stiff livers
This study looks at whether certain micro-RNA levels in your blood can help predict how your chronic liver disease is progressing. It is for people who already have some liver stiffness (measured by a special ultrasound) and are being treated at the University Hospital St. Pölten.
Sankt Pölten, Lower AustriaAges 18 years+ - NCT06449339RecruitingPhase 4
Beta-blocker study for early-stage liver scarring
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Hong KongAges 18 years+ - NCT06592820Recruiting
Ultrasound stiffness test for fatty liver disease
This study uses a special ultrasound technique, called shear wave elastography, to measure liver stiffness during an endoscopic ultrasound (EUS) procedure. It aims to see how well this new method detects liver scarring (fibrosis) in people with fatty liver disease, compared to standard tests like FibroScan and liver biopsy.
Boston, MassachusettsAges 18 years+ - NCT06658782Recruiting
MRI vs ultrasound for liver cancer detection in high-risk people
This trial compares two types of scans to see which detects liver cancer better in people at high risk. You would receive either an MRI with contrast or an ultrasound every 6 months to monitor for liver cancer.
Oxford, OxonAges 18 years+ - NCT06823713RecruitingPhase 1/Phase 2
Engineered immune cells for liver cirrhosis
This trial tests a personalized cell therapy made from your own white blood cells (called macrophages) that are engineered to help reduce scarring and inflammation in the liver. It is for people with liver cirrhosis due to fatty liver disease who have recently had a serious liver complication or need frequent fluid drainage.
BarcelonaAges 18–75 - NCT06855056Recruiting
Studying new markers for recovery from liver cirrhosis complications
This study looks at new blood markers to better predict recovery in patients hospitalized for complications of cirrhosis (like fluid buildup, confusion, or bleeding). You may qualify if you were recently hospitalized for these issues and are expected to go home soon.
Clichy, FranceAges 18–80 - NCT06863012Recruiting
Measuring liver pressure with endoscopy: a new method
This trial compares a newer, less invasive method (using an endoscope) to measure pressure in the liver's blood vessels with the standard technique. It may help people with liver disease or suspected cirrhosis better understand their condition.
Barcelona, BarcelonaAges 18–85 - NCT06871111RecruitingPhase 1
Bacteria treatment study for liver disease patients
This trial tests whether giving a mixture of helpful bacteria can improve gut health in people hospitalized with serious liver problems. It aims to see if restoring these bacteria can help with recovery.
Chicago, IllinoisAges 18 years+ - NCT06998862RecruitingPhase 3
Colchicine for people with chronic kidney disease
This trial tests whether colchicine, a drug that reduces inflammation, can help prevent further heart problems or strokes in people with moderate chronic kidney disease. You may be eligible if you have kidney disease and have had a heart attack, stroke, or related event in the past.
Madrid, MadridAges 18–99 - NCT07053488RecruitingPhase 1/Phase 2
Gene-edited liver transplant to lower rejection risk
This trial tests a liver transplant using a donor organ that has been gene-edited to reduce the risk of rejection. It may help people who need a liver transplant and are not a perfect tissue match with their donor.
Beijing, ChangpingAges 16–85 - NCT07119372RecruitingPhase 3
New drug for anemia from kidney disease on dialysis
This trial tests a new drug called BCD-131 (a biosimilar to Mircera) for treating anemia in people with kidney disease on dialysis. It compares the new drug to the standard treatment to see if it works just as well and is safe.
MinskAges 18–75 - NCT07122700Recruiting
Better tests for fatty liver disease in people with metabolic issues
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
Miami, FloridaAges 18–75 - NCT07275554Recruiting
Gene patterns and risk prediction in hepatitis B liver failure
This study looks at how gene changes (methylation) in people with hepatitis B-related liver failure may predict how well they will do. It aims to create a risk score to guide treatment.
Jinan, ShandongAges 18 years+
Hear when a new Chronic Liver Disease and Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease and cirrhosis?
- Yes. Clin2 currently lists 200 recruiting chronic liver disease and cirrhosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease and cirrhosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease and cirrhosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.